Cardiology journal最新文献

{"title":"Efficacy of tafamidis across age groups in ATTR-CM: insights from real-world data.","authors":"Catarina Gregório, João R Agostinho, Ana Abrantes, Marta Vilela, Margarida Batista, Filipa Abrantes, Ana Beatriz Garcia, Catarina Campos, Isabel Conceição, Fausto J Pinto, Dulce Brito","doi":"10.5603/cj.109146","DOIUrl":"10.5603/cj.109146","url":null,"abstract":"<p><strong>Introduction: </strong>Elderly patients with transthyretin amyloid cardiomyopathy (ATTR-CM) remain underrepresented in clinical trials. This study aimed to evaluate the effectiveness of tafamidis 61 mg in patients with ATTR-CM across different age groups.</p><p><strong>Material and methods: </strong>Patients with ATTR-CM treated with tafamidis 61 mg were stratified into age groups: < 75, 75-85, > 85 years. Clinical and echocardiographic data were collected at baseline and follow-up. The primary outcome - cardiovascular-related hospitalization and cardiovascular death - was assessed using Kaplan-Meier analysis.</p><p><strong>Results: </strong>A total of 89 patients with ATTR-CM were included: < 75 (n = 23), 75-85 (n = 40), and > 85 years (n = 26). Hereditary ATTR-CM was more prevalent in younger patients (p < 0.001). Older patients (≥ 75) were more often in NYHA class II/III (p = 0.009), required higher diuretic doses (p < 0.001), and had higher NT-proBNP (p = 0.002). At baseline, patients ≥ 75 years had greater maximal wall thickness (p < 0.001) and left ventricular mass (p = 0.034); global longitudinal strain was most impaired in those > 85 years (p = 0.039). Over a mean follow-up time of 27.4 ± 19.3 months, tafamidis treatment in patients > 85 years was associated with a greater reduction in NT-proBNP (p = 0.041) and in diuretic doses compared to those < 75 years (p = 0.044). No significant changes were observed in NYHA class, Kansas City Cardiomyopathy Questionnaire scores, or echocardiographic parameters. The composite outcome of cardiovascular-related hospitalization and cardiovascular death did not differ significantly among age groups (Log-Rank 5.71, p = 0.06).</p><p><strong>Conclusions: </strong>This study underscores the benefits of tafamidis in elderly patients, including those aged > 85 years, and supports its use across all age groups to improve cardiovascular outcomes in ATTR-CM.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":"33 ","pages":"e00226081"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13689992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149229489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative imaging in cardiac transthyretin amyloidosis: rationale and design of the i-CARE study.","authors":"Hendrea S A Tingen, Craig Balmforth, Neil Craig, Alwin Tubben, Magdalena M Dobrolinska, Shruti S Joshi, Marianna Fontana, Fabian Aus dem Siepen, David E Newby, Hans L A Nienhuis, Peter van der Meer, Ute Hegenbart, Thomas Wagner, Lucia Venneri, Vinoththa Visgnanamoorthy, Marc R Dweck, Riemer H J A Slart","doi":"10.5603/cj.106172","DOIUrl":"10.5603/cj.106172","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":"33 ","pages":"e00226046"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13189597/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147792167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evolution of concomitant mitral regurgitation in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: a prospective multi-center China-DVD2 cohort study.","authors":"Xiaohan Zhao, Ruisheng Zhang, Peng Li, Ying Guo, Xuyang Meng, Xiang Wang, You Zhong, Wenduo Zhang, Hui Li, Chenguang Yang, Yanqing Wu, Jianfang Luo, Xianbao Liu, Fang Wang, Huiping Zhang","doi":"10.5603/cj.103051","DOIUrl":"10.5603/cj.103051","url":null,"abstract":"<p><strong>Background: </strong>Severe aortic stenosis (AS) often coexists with mitral regurgitation (MR). This study evaluated the significant evolution of MR in patients undergoing transcatheter aortic valve replacement (TAVR) for AS.</p><p><strong>Methods: </strong>This multi-center China Degenerative Valve Disease II Cohort (China-DVD2) Study enrolled patients undergoing TAVR for AS from January 2020 to October 2023. MR severity was assessed at baseline and 12 months post-TAVR. Composite endpoints included all-cause death, heart failure rehospitalization, myocardial infarction, and angina.</p><p><strong>Results: </strong>Among 424 enrolled patients, 130 (31%) had significant MR at baseline. At 12 months, MR improved in 56 (70%) of 80 patients with follow-up, and greater improvement in left ventricular ejection fraction (LVEF) was associated with MR improvement [odds ratios (OR): 0.97, 95% confidence interval (CI): 0.95-1.00, p = 0.04)]. Patients with MR improvement showed significant New York Heart Association (NYHA) functional class improvement at 12-month follow-up. No survival benefit disparity was observed between patients with and without significant baseline MR, but a trend toward lower composite endpoint rate (12.5% vs. 20.8%, log-rank p = 0.49) was observed in patients with MR improvement. Older age [hazard ratios (HR): 1.12, 95% CI: 1.01-1.24, p = 0.04)] and higher systolic pulmonary arterial pressure (SPAP) (HR: 1.05, 95% CI: 1.00-1.09, p = 0.04) were linked to worse outcomes.</p><p><strong>Conclusions: </strong>Most patients with significant MR experienced improvement of NYHA class and MR post TAVR. Baseline significant MR was not linked to worse outcomes, but MR improvement showed a trend toward better prognosis. Older age and higher SPAP predicted worse outcomes.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"e00226005"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13189596/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing non-invasive differentiation in NSTE-ACS: role of PCAT radiomics.","authors":"Artur Dziewierz, Bernadeta Chyrchel, Tomasz Rakowski","doi":"10.5603/cj.106330","DOIUrl":"10.5603/cj.106330","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"e00226009"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13170443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145305031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the guidelines. Advanced endovascular therapies in a most challenging aortic coarctation case.","authors":"Wojciech Stecko, Piotr Wańczura, Andrzej Nowak, Robert Sabiniewicz","doi":"10.5603/cj.102385","DOIUrl":"10.5603/cj.102385","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"e00226006"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13170450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145024844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apolipoprotein B and atrial fibrillation - a clinical paradox with practical consequences.","authors":"Bartosz Maj, Burak Katipoglu, Łukasz Szarpak, Maciej Masłyk","doi":"10.5603/cj.111310","DOIUrl":"10.5603/cj.111310","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":"33 ","pages":"e00226038"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13170447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147679540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of intravascular imaging in optimizing renal denervation outcomes.","authors":"Karolina Jasińska-Gniadzik, Piotr Szwed, Aleksandra Gąsecka, Miłosz J Jaguszewski","doi":"10.5603/cj.101407","DOIUrl":"10.5603/cj.101407","url":null,"abstract":"<p><p>The 2023 ESH Guidelines recommend renal denervation (RDN) for patients with uncontrolled blood pressure (BP) and preserved kidney function despite optimal antihypertensive therapy, or intolerance to such therapy. Early trials (Symplicity HTN-1 and HTN-2) showed substantial BP reductions without serious complications, indicating a promising safety profile. However, subsequent trials revealed inconsistent results regarding BP reductions, highlighting the need for further investigation into RDN efficacy and patient selection criteria. RDN works by ablating sympathetic nerves in the renal artery adventitia, leading to thrombus formation, endothelial edema, vasospasm, and dissections. Intravascular imaging techniques like optical coherence tomography have advanced the understanding of these lesions. The previous discrepancies in clinical studies on RDN may stem not only from differences in procedural techniques, patient selection and study designs, but also by lack of standardized procedural outcomes, identified by intravascular imaging. The routine use of optical coherence tomography during RDN is still under debate and currently there is no clear correlation between focal vascular lesions and long-term BP reduction. However, recent data suggest that the use of intravascular imaging might potentially improve procedural outcomes by identifying the (desired) vascular changes directly after RDN. Here, the pathophysiology and imaging methods of RDN-induced vascular lesions are summarized, the association between vascular lesions and clinical effects of RDN, as well as current guidelines for peri- and postoperative pharmacotherapy after RDN.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":"e00226012"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13189622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145423619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can suPAR guide post-resuscitation management?","authors":"Łukasz Szarpak, Łukasz Szpinda, Michał Pruc, Maciej Masłyk, Katarzyna Kotfis","doi":"10.5603/cj.109314","DOIUrl":"10.5603/cj.109314","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":"33 ","pages":"e00226039"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13170442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147679535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apolipoprotein B in atrial fibrillation: marker of risk, not mechanism. Ceterum censeo Carthaginem esse delendam.","authors":"Marcin T Wełnicki, Stanisław Surma, Agnieszka Kapłon-Cieślicka, Maciej Janiszewski","doi":"10.5603/cj.112385","DOIUrl":"10.5603/cj.112385","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":"33 ","pages":"e00226066"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13524223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148820490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of ultrasound-assisted catheter-directed thrombolysis for central pulmonary embolism in intermediate-high-risk patients with increased bleeding risk in a rural hospital setting.","authors":"Mahmoud Oudeh, Hristo Kirov, Tulio Caldonazo, Angelique Runkel, Wasim Allakkiks, Kai Kögler, Torsten Doenst","doi":"10.5603/cj.103710","DOIUrl":"10.5603/cj.103710","url":null,"abstract":"<p><strong>Background: </strong>The EkoSonic Endovascular System (EKOS™) is an ultrasound-assisted catheter-directed thrombolysis (UACDT) device, which is becoming more popular for treatment of pulmonary embolism (PE) in patients with intermediate-high and high risk. Ultrasound waves help clot fragmentation and dissolution, therefore requiring less thrombolytic agent. With lower doses of thrombolysis, the bleeding risk is reduced but not eliminated. We aimed to evaluate the safety of this therapy in intermediate-high-risk central PE with intermediate and high bleeding risk.</p><p><strong>Methods: </strong>We retrospectively analyzed the database of a rural hospital between March 2021 and July 2024 for UACDT with EKOS™ in patients with intermediate-high-risk central PE and Registro Informatizado de la Enfermedad TromboEmbólica (RIETE) score ≥ 1. We evaluated procedure-related complications, bleeding events within the first 7 days, the need for further intervention, and all-cause in-hospital mortality.</p><p><strong>Results: </strong>Thirty patients underwent UACDT with EKOS™. Their mean age was 68 ± 15.6 years (30% ≥ 80 years). Deep vein thrombosis was present in 16 patients (53.3%). Access was via the brachial vein (23.3%) or the common femoral vein (76.7%). One patient had major bleeding from the access site. There were no other procedure-related major complications. Two patients had minor bleeding events. All bleeding events were managed conservatively without the need for blood transfusion. One patient (3.3%) died in-hospital due to multiple organ failure, and 86% of the patients (26/30) had no complications.</p><p><strong>Conclusions: </strong>Our analysis suggests that UACDT with EKOS™ is safe for the management of intermediate-high-risk central PE in patients with intermediate and high bleeding risk even in a rural hospital setting.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":"33 ","pages":"e00226053"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13189623/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147950292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}